Federal Register / Vol. 78, No. 4 / Monday, January 7, 2013 / Notices 941 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The applications will also be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than January 31, 

2013. 

A. Federal Reserve Bank of St. Louis 

(Yvonne Sparks, Community 

Development Officer) P.O. Box 442, St. 

Louis, Missouri 63166–2034: 

1. Jacksonville Bancorp, Inc., 

Jacksonville, Illinois; to become a bank 

holding company through the 

termination of the election by 

Jacksonville Savings Bank, Jacksonville, 

Illinois to be treated as a savings 

association. 

Dated: Board of Governors of the Federal 

Reserve System, January 2, 2013. 

Michael J. Lewandowski, 

Assistant Secretary of the Board. 

[FR Doc. 2013–00046 Filed 1–4–13; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

has taken final action in the following 

case: 

Paul J. Muchowski, Ph.D., The J. 

David Gladstone Institutes: Based on the 

report of an investigation conducted by 

The J. David Gladstone Institutes 

(Gladstone) and additional analysis 

conducted by ORI in its oversight 

review, ORI found that Dr. Paul J. 

Muchowski, former Senior Investigator, 

Gladstone Institute of Neurological 

Disease, Gladstone, engaged in research 

misconduct in research supported by 

National Institute of Neurological 

Diseases and Stroke (NINDS), National 

Institutes of Health (NIH), grant R01 

NS054753–06A1. 

ORI found that the Respondent 

engaged in research misconduct by 

falsifying and fabricating data that was 

included in one (1) funded NIH grant 

R01 NS054753–06A1 and two (2) 

submitted NIH grant applications R01 

NS054753–06 and R01 NS047237–06. 

Specifically, ORI finds that the 

Respondent knowingly and 

intentionally: 

• Falsely reported research 

experiments when the results did not 

exist at the time the grant applications 

were submitted. Specifically: 

fl in Figures 19–21 and related text 

of grant application R01 NS047237–06, 

the Respondent claimed he had 

successfully transduced human 

neuroblastoma SH–SY5Y cells 

expressing a-synuclein (aSyn) with 

lentiviruses containing small hairpin 

RNAs (shRNAs) that targeted Cog6, 

Stx7, Vps52, or Vps33a. The 

Respondent reported lentiviral 

expressed Cog6 significantly 

exacerbated a-Syn toxicity in SH–SY5Y 

cells, when only plasmid shRNAs were 

generated and utilized at the time the 

grant application was submitted. 

fl in Figure 5 and the accompanying 

text of grant R01 NS054753–06A1, the 

Respondent described the insertion of 

toxic and inert mutant huntingtin (htt) 

fragments into maltose binding proteinHtt-Cerulean constructs with a 

nonpathogenic (25Q) or pathogenic 

(46Q) polyQ repeat, with and without 

Cerulean. The modified proteins were 

claimed to have been purified, when the 

constructs had not been made at the 

time the grant was submitted. 

fl in Figures 5 and 6 and the 

accompanying text of grant R01 

NS054753–06A1, the Respondent 

claimed to have cloned toxic and inert 

mutant htt fragments into lentiviral 

constructs and generated lentiviruses, 

when the constructs were not made. 

fl in Figure 6 and related text in 

grant R01 NS054753–06A1, the 

Respondent claimed to have tested 

immunoblots of lysates from primary 

neurons with an antibody against 

mutant htt, which demonstrated that 

levels of htt expression in transduced 

cells were roughly equivalent to levels 

in normal neurons, when the 

experiment was not conducted. 

• Falsified Figure 3 of grant 

application R01 NS054753–06 by 

labeling the Western blot images for the 

expression of mutant htt in lentiviraltransduced primary neurons as ‘Cortex’ 

(left panel) and ‘Striatum’ (right panel), 

when the results were actually from the 

microglial cell lines N9 and BV2, 

respectively. 

Dr. Muchowski has entered into a 

Voluntary Settlement Agreement and 

has voluntarily agreed for a period of 

two (2) years, beginning on December 

10, 2012: 

(1) To have his research supervised; 

Respondent agreed that prior to the 

submission of an application for PHS 

support for a research project on which 

his participation is proposed and prior 

to his participation in any capacity on 

PHS-supported research, Respondent 

shall ensure that a plan for supervision 

of his duties is submitted to ORI for 

approval; the supervision plan must be 

designed to ensure the scientific 

integrity of his research contribution; he 

agreed that he shall not participate in 

any PHS-supported research until such 

a supervision plan is submitted to and 

approved by ORI; Respondent agreed to 

maintain responsibility for compliance 

with the agreed upon supervision plan; 

and 

(2) to exclude himself voluntarily 

from serving in any advisory capacity to 

PHS including, but not limited to, 

service on any PHS advisory committee, 

board, and/or peer review committee, or 

as a consultant. 

FOR FURTHER INFORMATION CONTACT: 

Director, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8200. 

David E. Wright, 

Director, Office of Research Integrity. 

[FR Doc. 2013–00010 Filed 1–4–13; 8:45 am] 

BILLING CODE 4150–31–P 


wreier-aviles on DSK7SPTVN1PROD with